Wyeth Plans Methylnaltrexone Studies In New Patient Populations
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.